Ching-Huai Ko

959 total citations
9 papers, 843 citations indexed

About

Ching-Huai Ko is a scholar working on Molecular Biology, Pharmacology and Biotechnology. According to data from OpenAlex, Ching-Huai Ko has authored 9 papers receiving a total of 843 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Biology, 3 papers in Pharmacology and 2 papers in Biotechnology. Recurrent topics in Ching-Huai Ko's work include Flavonoids in Medical Research (3 papers), Cell death mechanisms and regulation (2 papers) and Bioactive Compounds and Antitumor Agents (1 paper). Ching-Huai Ko is often cited by papers focused on Flavonoids in Medical Research (3 papers), Cell death mechanisms and regulation (2 papers) and Bioactive Compounds and Antitumor Agents (1 paper). Ching-Huai Ko collaborates with scholars based in Taiwan and United States. Ching-Huai Ko's co-authors include Shing‐Chuan Shen, Yen‐Chou Chen, W. Robert Lee, Hui-Yi Lin, Lingling Yang, Tony J.-F. Lee, Chun-Ming Shih, Yen‐Chou Chen, Lingling Yang and Chung-Wai Shiau and has published in prestigious journals such as PLoS ONE, Biochemical Pharmacology and European Journal of Pharmacology.

In The Last Decade

Ching-Huai Ko

9 papers receiving 824 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ching-Huai Ko Taiwan 9 470 222 213 143 97 9 843
Sung‐Moo Kim South Korea 20 525 1.1× 188 0.8× 122 0.6× 205 1.4× 92 0.9× 33 1.2k
Wenying Ren United States 12 674 1.4× 239 1.1× 169 0.8× 141 1.0× 256 2.6× 20 1.3k
Jen‐Jyh Lin Taiwan 20 599 1.3× 174 0.8× 241 1.1× 131 0.9× 59 0.6× 28 1.1k
Kyoo Seok Ahn South Korea 18 420 0.9× 156 0.7× 100 0.5× 126 0.9× 80 0.8× 38 845
Hye‐Sook Seo South Korea 18 532 1.1× 97 0.4× 201 0.9× 177 1.2× 100 1.0× 27 936
Pallavi Mandave India 5 421 0.9× 162 0.7× 115 0.5× 79 0.6× 132 1.4× 7 855
Ming‐Der Shi Taiwan 13 357 0.8× 157 0.7× 135 0.6× 144 1.0× 82 0.8× 20 745
Barbora Orlikova Luxembourg 18 444 0.9× 99 0.4× 244 1.1× 79 0.6× 69 0.7× 23 926
Chung Ho Ryu South Korea 20 536 1.1× 191 0.9× 140 0.7× 112 0.8× 217 2.2× 32 1.0k
Youn Kyung Choi South Korea 19 440 0.9× 105 0.5× 152 0.7× 157 1.1× 86 0.9× 36 957

Countries citing papers authored by Ching-Huai Ko

Since Specialization
Citations

This map shows the geographic impact of Ching-Huai Ko's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ching-Huai Ko with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ching-Huai Ko more than expected).

Fields of papers citing papers by Ching-Huai Ko

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ching-Huai Ko. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ching-Huai Ko. The network helps show where Ching-Huai Ko may publish in the future.

Co-authorship network of co-authors of Ching-Huai Ko

This figure shows the co-authorship network connecting the top 25 collaborators of Ching-Huai Ko. A scholar is included among the top collaborators of Ching-Huai Ko based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ching-Huai Ko. Ching-Huai Ko is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

9 of 9 papers shown
1.
Su, Jung-Chen, Ping‐Hui Tseng, Wei‐Tien Tai, et al.. (2014). RFX1-dependent activation of SHP-1 induces autophagy by a novel obatoclax derivative in hepatocellular carcinoma cells. Oncotarget. 5(13). 4909–4919. 25 indexed citations
2.
Lin, Chih‐Lung, Nai‐Jung Chiang, Chueh‐Chuan Yen, et al.. (2013). Selecting Tyrosine Kinase Inhibitors for Gastrointestinal Stromal Tumor with Secondary KIT Activation-Loop Domain Mutations. PLoS ONE. 8(6). e65762–e65762. 17 indexed citations
3.
Ko, Ching-Huai, et al.. (2013). Differential Proteomic Analysis of Cancer Stem Cell Properties in Hepatocellular Carcinomas by Isobaric Tag Labeling and Mass Spectrometry. Journal of Proteome Research. 12(8). 3573–3585. 14 indexed citations
4.
Shiau, Chung-Wai, Ching-Huai Ko, Chih-Lung Lin, et al.. (2011). Pharmacophore modeling and virtual screening to identify potential RET kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 21(15). 4490–4497. 13 indexed citations
5.
Tai, Wei‐Tien, Ann‐Lii Cheng, Chung-Wai Shiau, et al.. (2011). Dovitinib Induces Apoptosis and Overcomes Sorafenib Resistance in Hepatocellular Carcinoma through SHP-1–Mediated Inhibition of STAT3. Molecular Cancer Therapeutics. 11(2). 452–463. 113 indexed citations
6.
Ko, Ching-Huai, Shing‐Chuan Shen, Tony J.-F. Lee, & Yen‐Chou Chen. (2005). Myricetin inhibits matrix metalloproteinase 2 protein expression and enzyme activity in colorectal carcinoma cells. Molecular Cancer Therapeutics. 4(2). 281–290. 111 indexed citations
8.
Chen, Yen‐Chou, Shing‐Chuan Shen, W. Robert Lee, et al.. (2002). Wogonin and fisetin induction of apoptosis through activation of caspase 3 cascade and alternative expression of p21 protein in hepatocellular carcinoma cells SK-HEP-1. Archives of Toxicology. 76(5-6). 351–359. 147 indexed citations
9.
Shen, Shing‐Chuan, W. Robert Lee, Hui-Yi Lin, et al.. (2002). In vitro and in vivo inhibitory activities of rutin, wogonin, and quercetin on lipopolysaccharide-induced nitric oxide and prostaglandin E2 production. European Journal of Pharmacology. 446(1-3). 187–194. 201 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026